⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 3, 2022Annals of the Rheumatic DiseasesOpen Access

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Philip J. Mease Atul Deodhar Désirée van der Heijde Frank Behrens Alan Kivitz Jeffrey Neal Jonghyeon Kim Shalabh Singhal Miroslawa Nowak Subhashis Banerjee

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct03881059.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mease et al. (2022) studied this question.

synapsesocial.com/papers/69d850c0f4e559c61eae36ea https://doi.org/10.1136/annrheumdis-2021-221664

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Psoriatic ArthritisOriginal Research · 2017 · 1,470 citations
2Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studiesMeta-Analysis · 2020 · 15 citations
3Psoriatic arthritis for dermatologistsHuman Clinical Trial · 2019 · 89 citations
4Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with PsoriasisOriginal Research · 2014 · 271 citations
5Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domainEarly-Phase Clinical Trial · 2019 · 289 citations

More related papers

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis2020
Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis2020
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis2018

More from Annals of the Rheumatic Diseases

Immune reset in rheumatic autoimmune disease: from a tantalising metaphor to a measurable therapeutic stateThu,
Immune reset after deep B-lineage depletion: remission is not reprogrammingTue,